Claritas (Formerly Kalytera Therapeutics) Cites Data by Massachusetts General Hospital and Others Demonstrating the Effectiveness of Nitric Oxide as a Potential Therapy for COVID-19 Infection and Validating the Potential of R-107 in this Indication
March 02, 2021 at 08:30 am
Share
Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) announced that compelling data demonstrating that nitric oxide achieved viral clearance in severe and critical COVID-19 patients validates the potential of the Company’s proprietary nitric oxide releasing compound, R-107, as a therapy for coronavirus and COVID-19 infection. R-107 is a nitric oxide-releasing compound. Nitric oxide is being evaluated by both industry and academic groups as a potential treatment for COVID-19 infection. Initial data from some of these studies have been announced. These data are exceptionally positive. Data from a clinical study conducted by Massachusetts General Hospital (“Mass General”) in pregnant patients with severe and critical COVID-19 infection demonstrated viral clearance by 22 days after COVID-19 diagnosis in 5 of 6 patients who received inhaled nitric oxide gas, but no other antiviral medication. In vitro data from studies conducted by Know Bio, LLC demonstrate that nitric oxide can inhibit viral reproduction of SARS-CoV-2, the coronavirus that causes COVID-19. Multiple nitric oxide-releasing compounds were tested against wild type SARS-CoV-2 virus. The result was a greater than 99.9% reduction in virus observed after 24 hours, versus virus observed in untreated cells. Uppsala University in Sweden announced in vitro data demonstrating the dose dependent antiviral effect of nitric oxide on SARS-CoV-2 replication. Novan, Inc. announced positive in vitro results showing the potential efficacy of nitric oxide as an antiviral against SARS-CoV-2, the virus that causes COVID-19 infection. Novan’s studies were conducted at the Institute for Antiviral Research at Utah State University. The data announced by Mass General are of particular interest. Six pregnant patients with severe and critical COVID-19 infection began rescue therapy with inhaled nitric oxide within 48 hours from hospital admission. The treatment was well tolerated, and no side effects were observed. By day 22, five of the six patients, who received no other antiviral medication, tested negative twice for SARS-CoV-2. All six patients were discharged, and have now delivered healthy, COVID-19 free, infants. These data represent a breakthrough in the potential treatment of COVID-19 infection. The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâs products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.
Claritas (Formerly Kalytera Therapeutics) Cites Data by Massachusetts General Hospital and Others Demonstrating the Effectiveness of Nitric Oxide as a Potential Therapy for COVID-19 Infection and Validating the Potential of R-107 in this Indication